Predictors of Response to Vedolizumab in Patients with Ulcerative Colitis: Results from the Greek VEDO-IBD Cohort.

Giorgos BamiasGeorgios KokkotisMichalis GizisChristina KapizioniKonstantinos KarmirisEvgenia KouretaNikolaos KyriakosGeorgios LeonidakisKonstantinos MakrisPanagiotis MarkopoulosGeorgios MichalopoulosSpyridon MichopoulosIoannis PapaconstantinouDimitrios PolymerosSpyros I SiakavellasKonstantinos TriantafyllouEftychia TsironiEmmanouela TsoukaliMaria TzouvalaNikos ViazisVassileios XourafasEirini ZacharopoulouEvanthia ZampeliKonstantinos ZografosGeorge PapatheodoridisGerasimos Mantzaris

Published in: Digestive diseases and sciences (2021)

Vedolizumab is characterized by high efficacy and long-term treatment persistence in UC. More aggressive disease, as indicated by refractoriness to steroids or anti-TNFs and elevated baseline PROs, may predict suboptimal response and help pre-treatment prognostic stratification of patients.

Keyphrases

ulcerative colitis
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
patients with inflammatory bowel disease